Physician profile
Bernie C Ranchero
NPI 1568656445
$533,120.40
in general payments reported to CMS, 2019-2025
58 companies · $107K in 2025
The $107K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73K · 2020: $36K · 2021: $78K · 2022: $64K · 2023: $55K · 2024: $120K · 2025: $107K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $247K · Food and Beverage: $18K · Travel and Lodging: $16K · Consulting Fee: $750 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $247,108.32 |
| Food and Beverage | $17,990.48 |
| Travel and Lodging | $16,249.45 |
| Consulting Fee | $750.00 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $322,291.70 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $74,505.64 | 2019-2025 | Spravato, Xarelto |
| Amgen INC. | $61,266.35 | 2019-2025 | Otezla, Otezla, Repatha |
| Abbvie INC. | $24,091.34 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $23,675.91 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Phathom Pharmaceuticals, INC. | $9,290.50 | 2024-2025 | Voquezna |
| Eisai INC. | $3,739.84 | 2020-2021 | |
| Eli Lilly and Company | $1,800.00 | 2025 | Zepbound |
| Lilly USA, LLC | $1,523.71 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $1,215.61 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $996.93 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Novartis Pharmaceuticals Corporation | $860.60 | 2019-2025 | |
| Pfizer INC. | $856.10 | 2019-2025 | |
| Allergan, INC. | $680.56 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $561.52 | 2019-2024 | Verquvo, Belsomra |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernie Ranchero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.